As COVID-19 makes its way around the world, Syntegon Technology has a lot going on behind the scenes to support this ever-changing situation. Along with the research and development efforts for novel vaccines, Syntegon is providing solid solutions regarding fill-finish.
Syntegon developed and offers a highly flexible, medium output …more
You’re invited! Syntegon is excited to be a presenting sponsor at Virtual Pharma Expo 2020. This live event will feature presentations by leading experts from …more
How does quality assurance for syringes work?
Inspection of different container types can be a challenge – but any problem can be solved with the right know-how and technology.
…more
Downtime, product waste and low machine output are all factors that erode efficiency and productivity. It is best to prevent problems before they happen and bring the highest performance to your production. Industry 4.0 digital solutions from Syntegon offer you …more
Our 80,000 square foot site has 50,000 square feet of assembly and manufacturing, and is home to 130 employees with an average tenure of 16 years! As the North American headquarters for pharma solid and liquid, Minneapolis is full of engineers, customer service, sales, validation, assembly and manufacturing personnel to help throughout the entire equipment lifecycle.
Hans Treschel and Al Larson founded TL Systems in 1970. In 1992 our current building was built, and …more
The Minneapolis plant of Syntegon is proud to announce the delivery of its latest animal health pharmaceuticals filling line featuring a closed restricted access barrier system for ultimate operator protection.
Animals play an integral part of our lives, from the food we eat, to our companions. No matter what role animals play in our lives, their health is important. Whether protecting the herd from bovine respiratory disease or treating Fido’s kennel cough, the medicines that keep animal populations healthy …more
Changes are coming for many peristaltic PreVAS system users. In order to support you with single-use solutions, Syntegon has extended our cooperation with Sartorius Stedim Biotech. Moving forward, Sartorius will directly supply current and future peristaltic single-use systems to end users, shortening the supply chain. This includes direct order placement to Sartorius and direct shipments from Sartorius. Questions concerning single-use system materials (i.e. certificates, bag, extractables, etc.) …more
With social distancing and work from home directives in place in many companies across North America and other parts of the world, research and development projects may be slowing down due to the lacking availability of lab time. Our partner labs are fully operational and are here to help you keep your projects on track during this challenging time. If you need support, feel free to reach out to …more
In the midst of our current, ever-changing worldwide coronavirus crisis, the word on everyone’s mind is vaccine. Never before have the world’s scientific and pharmaceutical communities felt such a collective rush to bring life-saving vaccines to market. In today’s post, our resident filling systems and single-use technology expert, Dr. Laura Moody, provides an overview of the different types of vaccines, how they work, and how Syntegon’s fill-finish portfolio supports clinical and commercial manufacturing.
The intention behind a vaccine is to train the body’s immune cells …more
FLT #16 configured to fill gene therapy products in an isolator
The Minneapolis plant of Syntegon is proud to announce the delivery of its 16th and 17th model FLT small batch vial filler for ATMP applications. Configured to fill gene therapy products in an isolator and oncolytic immunotherapies and vaccines in a RABS, respectively, these latest deliveries of the proven FLT platform for RTU vials exemplify the trend towards smaller batches of higher value products and highlight Syntegon’s track record of providing solutions that meet the exacting requirements of the rapidly growing ATMP segment.
The Syntegon FLT vial filler is designed …more
